BioInvent International AB (publ), a clinical-stage company, discovers, researches, and develops novel immuno-modulatory antibodies for the treatment of cancer in Sweden, Europe, the United States, and internationally. Its drug candidates are BI-1808 is in phase 2 clinical trial and BI-1910 in phase 1 clinical trial for solid tumors targeting Tumor necrosis factor receptor-2 (TNFR2); BI-1206/rituximab in phase 2 clinical trial for the treatment of non-Hodgkin's lymphoma; BI-1206/pembrolizumab and BI-1607/trastuzumab in phase 1 clinical trial to treat solid tumors targeting FCYRIIB; and BT-001 in phase 1 clinical trial for the treatment of solid tumors targeting Cytotoxic T lymphocyte-associated protein-4. The company has a partnership and collaboration with Transgene to develop BT-001 oncolytic viruses for treatment of solid tumors; and collaboration and supply agreement with Merck to evaluate BI-1206, BI-1808, and BT-001 in combination with Keytruda; and licensing agreement with CASI pharmaceuticals for BI-1206. The company was incorporated in 1996 and is based in Lund, Sweden.
| 45.36 | |
| 45.94 | |
| - | |
| 45.85 | |
| 44.48 | |
| 14.44-50.8 | |
| 3 011 M | |
| 65 804 K | |
| 38 636 K | |
| -1.4777 | |
| 0.38 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
Well-tolerated infusions, no dose limiting toxicities or serious adverse events Stable disease observed in six patients so far; efficacy to be further explored in Phase 2a LUND, SWEDEN / ACCESSWIRE /...
LUND, SWEDEN / ACCESSWIRE / June 13, 2023 / BioInvent International (STO:BINV) Abstract for the ongoing clinical trial with BI-1206 in combination with rituximab has been accepted to the ICML and show...
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
